Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bermejo

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
European Journal of Gastroenterology & Hepatology|April 7, 2020
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's diseaseMaría Chaparro, Iván Guerra, Marisa Iborra, et al.
Journal of Crohn'S & Colitis|December 4, 2013
Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care UnitsXavier Calvet, Julián Panés, Noelia Alfaro, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseMaría Chaparro, Adrià Aterido, Iván Guerra, et al.
Inflammatory Bowel Diseases|April 23, 2019
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA RegistryFiorella Cañete, Míriam Mañosa, María José Casanova, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU StudyTiago Nunes, Manuel Barreiro-de Acosta, Pilar Nos, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
The American Journal of Gastroenterology|November 26, 2024
Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study)María José García, Yanire Brenes, Miren Vicuña, et al.
Journal of Crohn'S & Colitis|September 24, 2020
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA RegistryMaría Chaparro, Ana Garre, Francisco Mesonero, et al.
Journal of Medical Virology|January 14, 2023
Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trialAlejandro Morales-Ortega, Ana Isabel Farfán-Sedano, Juan Víctor San Martín-López, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
European Journal of Gastroenterology & Hepatology|April 7, 2020
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's diseaseMaría Chaparro, Iván Guerra, Marisa Iborra, et al.
Journal of Crohn'S & Colitis|December 4, 2013
Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care UnitsXavier Calvet, Julián Panés, Noelia Alfaro, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseMaría Chaparro, Adrià Aterido, Iván Guerra, et al.
Inflammatory Bowel Diseases|April 23, 2019
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA RegistryFiorella Cañete, Míriam Mañosa, María José Casanova, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU StudyTiago Nunes, Manuel Barreiro-de Acosta, Pilar Nos, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
The American Journal of Gastroenterology|November 26, 2024
Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study)María José García, Yanire Brenes, Miren Vicuña, et al.
Journal of Crohn'S & Colitis|September 24, 2020
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA RegistryMaría Chaparro, Ana Garre, Francisco Mesonero, et al.
Journal of Medical Virology|January 14, 2023
Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trialAlejandro Morales-Ortega, Ana Isabel Farfán-Sedano, Juan Víctor San Martín-López, et al.
Pageof 14